Correlation Between Amylyx Pharmaceuticals and Pliant Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Amylyx Pharmaceuticals and Pliant Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Amylyx Pharmaceuticals and Pliant Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Amylyx Pharmaceuticals and Pliant Therapeutics, you can compare the effects of market volatilities on Amylyx Pharmaceuticals and Pliant Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Amylyx Pharmaceuticals with a short position of Pliant Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Amylyx Pharmaceuticals and Pliant Therapeutics.

Diversification Opportunities for Amylyx Pharmaceuticals and Pliant Therapeutics

0.31
  Correlation Coefficient

Weak diversification

The 3 months correlation between Amylyx and Pliant is 0.31. Overlapping area represents the amount of risk that can be diversified away by holding Amylyx Pharmaceuticals and Pliant Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pliant Therapeutics and Amylyx Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Amylyx Pharmaceuticals are associated (or correlated) with Pliant Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pliant Therapeutics has no effect on the direction of Amylyx Pharmaceuticals i.e., Amylyx Pharmaceuticals and Pliant Therapeutics go up and down completely randomly.

Pair Corralation between Amylyx Pharmaceuticals and Pliant Therapeutics

Given the investment horizon of 90 days Amylyx Pharmaceuticals is expected to generate 0.36 times more return on investment than Pliant Therapeutics. However, Amylyx Pharmaceuticals is 2.78 times less risky than Pliant Therapeutics. It trades about 0.03 of its potential returns per unit of risk. Pliant Therapeutics is currently generating about -0.17 per unit of risk. If you would invest  384.00  in Amylyx Pharmaceuticals on December 29, 2024 and sell it today you would earn a total of  3.00  from holding Amylyx Pharmaceuticals or generate 0.78% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Amylyx Pharmaceuticals  vs.  Pliant Therapeutics

 Performance 
       Timeline  
Amylyx Pharmaceuticals 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Amylyx Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating essential indicators, Amylyx Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.
Pliant Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Pliant Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Amylyx Pharmaceuticals and Pliant Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Amylyx Pharmaceuticals and Pliant Therapeutics

The main advantage of trading using opposite Amylyx Pharmaceuticals and Pliant Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Amylyx Pharmaceuticals position performs unexpectedly, Pliant Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pliant Therapeutics will offset losses from the drop in Pliant Therapeutics' long position.
The idea behind Amylyx Pharmaceuticals and Pliant Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance